BACKGROUND AND PURPOSE: Stroke is a leading cause of disability. Rehabilitation robotics have been developed to aid in recovery after a stroke. This study determined the additional cost of robot-assisted therapy and tested its cost-effectiveness. METHODS: We estimated the intervention costs and tracked participants' healthcare costs. We collected quality of life using the Stroke Impact Scale and the Health Utilities Index. We analyzed the cost data at 36 weeks postrandomization using multivariate regression models controlling for site, presence of a prior stroke, and Veterans Affairs costs in the year before randomization. RESULTS: A total of 127 participants were randomized to usual care plus robot therapy (n=49), usual care plus intensive comparison therapy (n=50), or usual care alone (n=28). The average cost of delivering robot therapy and intensive comparison therapy was $5152 and $7382, respectively (P<0.001), and both were significantly more expensive than usual care alone (no additional intervention costs). At 36 weeks postrandomization, the total costs were comparable for the 3 groups ($17 831 for robot therapy, $19 746 for intensive comparison therapy, and $19 098 for usual care). Changes in quality of life were modest and not statistically different. CONCLUSIONS: The added cost of delivering robot or intensive comparison therapy was recuperated by lower healthcare use costs compared with those in the usual care group. However, uncertainty remains about the cost-effectiveness of robotic-assisted rehabilitation compared with traditional rehabilitation. Clinical Trial Registration- URL: http://clinicaltrials.gov. Unique identifier: NCT00372411.
RCT Entities:
BACKGROUND AND PURPOSE:Stroke is a leading cause of disability. Rehabilitation robotics have been developed to aid in recovery after a stroke. This study determined the additional cost of robot-assisted therapy and tested its cost-effectiveness. METHODS: We estimated the intervention costs and tracked participants' healthcare costs. We collected quality of life using the Stroke Impact Scale and the Health Utilities Index. We analyzed the cost data at 36 weeks postrandomization using multivariate regression models controlling for site, presence of a prior stroke, and Veterans Affairs costs in the year before randomization. RESULTS: A total of 127 participants were randomized to usual care plus robot therapy (n=49), usual care plus intensive comparison therapy (n=50), or usual care alone (n=28). The average cost of delivering robot therapy and intensive comparison therapy was $5152 and $7382, respectively (P<0.001), and both were significantly more expensive than usual care alone (no additional intervention costs). At 36 weeks postrandomization, the total costs were comparable for the 3 groups ($17 831 for robot therapy, $19 746 for intensive comparison therapy, and $19 098 for usual care). Changes in quality of life were modest and not statistically different. CONCLUSIONS: The added cost of delivering robot or intensive comparison therapy was recuperated by lower healthcare use costs compared with those in the usual care group. However, uncertainty remains about the cost-effectiveness of robotic-assisted rehabilitation compared with traditional rehabilitation. Clinical Trial Registration- URL: http://clinicaltrials.gov. Unique identifier: NCT00372411.
Authors: Albert C Lo; Peter D Guarino; Lorie G Richards; Jodie K Haselkorn; George F Wittenberg; Daniel G Federman; Robert J Ringer; Todd H Wagner; Hermano I Krebs; Bruce T Volpe; Christopher T Bever; Dawn M Bravata; Pamela W Duncan; Barbara H Corn; Alysia D Maffucci; Stephen E Nadeau; Susan S Conroy; Janet M Powell; Grant D Huang; Peter Peduzzi Journal: N Engl J Med Date: 2010-04-16 Impact factor: 91.245
Authors: Albert C Lo; Peter Guarino; Hermano I Krebs; Bruce T Volpe; Christopher T Bever; Pamela W Duncan; Robert J Ringer; Todd H Wagner; Lorie G Richards; Dawn M Bravata; Jodie K Haselkorn; George F Wittenberg; Daniel G Federman; Barbara H Corn; Alysia D Maffucci; Peter Peduzzi Journal: Neurorehabil Neural Repair Date: 2009-06-18 Impact factor: 3.919
Authors: Bruce T Volpe; Daniel Lynch; Avrielle Rykman-Berland; Mark Ferraro; Michael Galgano; Neville Hogan; Hermano I Krebs Journal: Neurorehabil Neural Repair Date: 2008-01-09 Impact factor: 3.919
Authors: Giovanni Di Pino; Giovanni Pellegrino; Giovanni Assenza; Fioravante Capone; Florinda Ferreri; Domenico Formica; Federico Ranieri; Mario Tombini; Ulf Ziemann; John C Rothwell; Vincenzo Di Lazzaro Journal: Nat Rev Neurol Date: 2014-09-09 Impact factor: 42.937
Authors: Helen Rodgers; Helen Bosomworth; Hermano I Krebs; Frederike van Wijck; Denise Howel; Nina Wilson; Tracy Finch; Natasha Alvarado; Laura Ternent; Cristina Fernandez-Garcia; Lydia Aird; Sreeman Andole; David L Cohen; Jesse Dawson; Gary A Ford; Richard Francis; Steven Hogg; Niall Hughes; Christopher I Price; Duncan L Turner; Luke Vale; Scott Wilkes; Lisa Shaw Journal: Health Technol Assess Date: 2020-10 Impact factor: 4.014